Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.
Exploring the companies and themes that make up this emerging and exciting new sector
Psychedelic Drug Patenting: Still Only Scratching The Surface
Dozens of psychedelic drugs to research. Several "generations" of R&D ahead. To say that we're early in the game with psychedelic drug research is an understatement.
TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche
Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.
Looking For The Perfect Inflation Hedge? Try This Company
Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Veterans Push to Persuade Lawmakers to Legalize Therapeutic Use of Psychedelics
New studies have indicated psilocybin could be useful in the treatment of everything from major depression to alcoholism.
Mydecine Announces Reverse Stock-Split
Mydecine Innovations Group announces a share consolidation of 1 post-consolidation share for every 50 pre-consolidation shares.
Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds
Delic Holdings announces receiving a Health Canada 56 Research Exemption to conduct research on various psychedelic drugs.
Red Light Holland Sponsors First Of Its Kind Group Microdosing Concert In The Netherlands
Red Light Holland to sponsor a "microdosing concert" in The Netherlands, given by mezza-soprano Helena van Heel.
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
Awakn Life Sciences reports that it now has three clinics in operation, including its new flagship clinic in London.
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues.
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Numinus Wellness is acquiring Novamind Inc in an all-share deal valued at CAD$26.2 million, creating an industry leader in research AND treatment.
Magic mushrooms can lead to long-term improvements in depression, study finds
Magic mushroom's drug psilocybin can lead to long-term improvements in depression symptom severity, a small study has found.